Centene’s post-2025 “big reset” is turning into a 2026 margin-led rebound—just as OBBBA rewires Medicaid economics and forces managed care to get leaner, faster.
The managed care industry is currently traversing one of the most volatile periods in its modern history, characterized by a fundamental shift in the relationship between government-sponsored programs and private insurance intermediaries. At the epicenter of this transformation is Centene Corporation, an organization that has served as a primary conduit for Medicaid and Health Insurance Marketplace coverage for over three decades.[1, 2, 3] Following a turbulent 2025 fiscal year, defined by a massive $6.7 billion non-cash impairment loss and a significant contraction in equity value, the enterprise has entered 2026 with a disciplined strategy of margin restoration and portfolio rationalization.[1, 4, 5] The first quarter of 2026 has emerged as a pivotal inflection point, with the company reporting adjusted diluted earnings per share of $3.37, a figure that not only surpassed internal projections but also signaled a robust recovery in its core Medicaid and Marketplace segments.[6, 7, 8] This resurgence is occurring against a backdrop of sweeping legislative reform, most notably the One Big Beautiful Bill Act (OBBBA), which introduces nearly $1 trillion in federal Medicaid cuts and mandates stringent new eligibility requirements that will reshape the American healthcare landscape through 2034.[9, 10, 11, 12]
To understand the trajectory of Centene in 2026, one must first analyze the "Big Reset" of 2025. This period was marked by a sharp divergence between top-line revenue growth and bottom-line profitability. Total revenues for 2025 reached $194.8 billion, representing a 19.4% increase over 2024, yet the company reported a GAAP net loss of $6.67 billion.[13, 14, 15] The primary driver of this loss was a $6.72 billion non-cash goodwill impairment charge, triggered by a decline in the company’s stock price and the enactment of the OBBBA in July 2025.[1, 4, 5] These impairments were concentrated in the company’s Medicaid and Marketplace reporting units, reflecting a revised outlook on membership morbidity and rate adequacy.[1, 5]
The structural realignment was further evidenced by the divestiture of non-core assets. In late 2025, Centene signed a definitive agreement to divest the remaining portions of Magellan Health, resulting in an additional $513 million impairment charge.[4, 16] This decision marked the culmination of a multi-year effort to simplify the enterprise’s footprint and focus on its high-scale government-sponsored insurance programs.[17, 18] The sale of Circle Health in early 2024 for approximately $931 million and the divestiture of Operose Health Group and Collaborative Health Systems (CHS) underscored management's conviction that operational complexity must be sacrificed for margin stability.[17, 19]
The historical financial data illustrates a period of rapid inorganic expansion followed by the current phase of disciplined contraction.
| Fiscal Year | Total Revenue (Millions) | Net Income/Loss (Millions) | GAAP Diluted EPS | Adjusted Diluted EPS | Consolidated HBR |
|---|---|---|---|---|---|
| 2020 | $111,115 | $1,808 | $3.12 (est) | N/A | N/A |
| 2021 | $125,982 | $1,347 | $2.31 (est) | N/A | N/A |
| 2022 | $144,547 | $1,202 | $2.07 (est) | N/A | N/A |
| 2023 | $153,999 | $2,702 | $4.85 (est) | $6.68 | 87.7% |
| 2024 | $163,071 | $3,305 | $6.31 | $7.17 | 88.3% |
| 2025 | $194,777 | $(6,674) | $(13.53) | $2.08 | 91.9% |
[1, 4, 13, 14, 15, 20, 21]
The increase in the Health Benefits Ratio (HBR) from 87.7% in 2023 to 91.9% in 2025 is a critical metric for industry analysts. This upward trend reflects the cumulative impact of several factors: the expiration of the Public Health Emergency (PHE) continuous coverage provisions, which led to a "deterioration in risk mix" as healthier members exited the Medicaid rolls, and a surge in utilization for behavioral health services and high-cost specialty drugs.[1, 22, 23, 24]
The transition into 2026 has been characterized by an aggressive repricing of the company’s product portfolio and a rigorous focus on medical cost containment. The first quarter 2026 earnings report, released on April 28, 2026, demonstrated the efficacy of these measures.[6, 7] Centene reported adjusted diluted EPS of $3.37, which was approximately $0.50 better than the company’s internal expectations and significantly higher than the $2.13 consensus forecast.[7, 8]
Total revenues for the quarter were $49.94 billion, a 7.1% increase compared to the prior year period.[25, 26] This revenue growth was particularly impressive given the substantial drop in Marketplace membership, as it was driven by premium yield improvements and strong growth in the Medicare Prescription Drug Plan (PDP) segment.[7, 27]
The core of Centene's Q1 2026 beat was the improvement in its segmented HBRs, which indicated a stabilization of medical costs.
| Business Segment | Q1 2026 Revenue (Millions) | Q1 2026 HBR | Change in HBR (YoY) | Membership (03/31/2026) |
|---|---|---|---|---|
| Medicaid | $23,596 | 93.1% | -50 bps | 12,426,900 |
| Commercial | $9,556 | 75.3% | N/A | 4,063,200 |
| Medicare | $10,326 | 84.9% | N/A | 9,782,800 |
| Other | $1,177 | N/A | N/A | N/A |
| Total Premium & Service | $44,655 | 87.3% | -20 bps | 26,272,900 |
[6, 7, 27]
In the Medicaid segment, the 50-basis point improvement in HBR to 93.1% was a result of successful rate negotiations with state partners and a more moderate flu season than originally anticipated.[7, 8, 27, 28] Management noted that this represented the third consecutive quarter of progress in managing Medicaid medical costs, suggesting that the "trough" of Medicaid margins may have been reached in 2025.[24, 28]
The Commercial segment, which is dominated by the ACA Marketplace, reported an HBR of 75.3%.[7, 29] While this was slightly above internal expectations due to higher acuity among Silver Tier members, it reflected the impact of a deliberate 30% average premium increase implemented to restore profitability.[30, 31, 32] The Medicare segment HBR of 84.9% was a "standout" performance, driven by outperformance in both the Medicare Advantage and PDP offerings.[7, 28]
Centene remains the nation's largest Medicaid Managed Care Organization (MCO), serving approximately 1 in 15 individuals across 30 states.[1, 3, 33] This scale provides a significant competitive moat, as the enterprise leverages multi-year state contracts and localized provider networks to manage high-needs populations.[2, 34] However, the Medicaid business has been the primary source of volatility in recent years due to the "unwinding" of the PHE continuous coverage provisions.[22, 24]
Between March 2023 and December 2025, Centene’s Medicaid enrollment declined by 3.8 million members, or 23.3%.[24] This decline was consistent with national trends as states resumed eligibility redeterminations. The impact on the risk pool has been significant; as healthier individuals exited the program, the remaining "high acuity" members have driven up the average medical cost per member.[1, 4, 20]
To counter this, Centene has focused on "actuarial soundness" in its rate discussions with states. In 2025, the company achieved Medicaid rate increases of 5.5%, and for 2026, it anticipates a composite rate yield of approximately 4.5%.[8, 32] Management has emphasized that their 2026 guidance assumes a net medical cost trend in the mid-4% range, which aligns with these rate increases.[28, 35]
| State Medicaid Footprint (Select) | Brand Names | Core Programs Served |
|---|---|---|
| California | Health Net | Expansion, ABD, LTSS |
| Florida | Sunshine Health | TANF, CHIP, LTSS |
| Texas | Superior HealthPlan | TANF, Foster Care, ABD |
| New York | Fidelis Care | Expansion, CHIP, Duals |
| Georgia | Peach State Health Plan | TANF, ABD |
| Ohio | Buckeye Health Plan | Expansion, ABD |
[3, 19]
Centene’s strategy involves not just scale but "local operating depth".[2] This allows the company to partner with states on "state-directed payments" (SDPs), which are used to support safety-net hospitals and other providers. These payments have become a critical revenue stream, with Medicaid revenues increasing by 6% in Q1 2026 even as membership declined.[7, 24]
The One Big Beautiful Bill Act (OBBBA), signed into law in July 2025, introduces the most significant structural changes to Medicaid since the ACA. The law is projected to reduce federal Medicaid spending by over $1 trillion over the next decade.[9, 10, 11, 12] For Centene, the OBBBA presents both an administrative burden and a long-term membership threat.
The most immediate change is the requirement for states to conduct semi-annual eligibility redeterminations for the Medicaid expansion population, starting December 31, 2026.[9, 12] This doubling of the redetermination frequency is expected to significantly increase "coverage churn," as individuals cycle between Medicaid, the Marketplace, and being uninsured.[9] Furthermore, the introduction of nationwide community engagement (work) requirements for able-bodied adults is expected to lead to the disenrollment of millions of individuals.[9, 11, 12] The Congressional Budget Office (CBO) estimates that the OBBBA will increase the number of uninsured individuals by 7.5 million to 10 million by 2034.[11, 12, 24]
Despite these headwinds, Centene's management believes that their scale and investment in IT systems will allow them to navigate the administrative complexity of more frequent eligibility checks.[10] Moreover, the company has successfully mitigated some Medicaid attrition by transitioning former Medicaid members to its ACA Marketplace plans.[2]
Centene’s Marketplace business, operated under the Ambetter brand, is the largest in the nation.[1, 33, 36] Following a period of aggressive enrollment growth fueled by enhanced premium tax credits, the segment faced a "margin collapse" in 2025 as medical costs outpaced premiums.[1, 4, 18]
For the 2026 plan year, Centene executed a major strategic shift, raising its Marketplace premiums by an average of mid-30% across states covering 95% of its membership.[1, 30, 31, 32, 37] This move was designed to restore pre-tax margins from a negative position in 2025 toward a long-term target of 4%.[37, 38]
The result was a sharp contraction in membership. Marketplace enrollment fell from 5.6 million in March 2025 to 3.58 million in March 2026.[7, 28] Management noted that much of this loss was concentrated among "non-paying" members or those who disenrolled following the expiration of subsidies.[32]
| Marketplace Enrollment Metrics | March 31, 2025 | March 31, 2026 | Change (%) |
|---|---|---|---|
| Marketplace Members | 5,626,000 | 3,582,200 | -36.3% |
| Bronze Tier Mix (%) | ~20% | >30% | +1000 bps |
| Silver Tier Mix (%) | ~75% | <65% | -1000 bps |
[7, 32, 39]
The shift toward Bronze plans is a significant development. Bronze enrollees, who typically have lower premiums and higher deductibles, now make up more than 30% of Centene’s Marketplace membership.[32] While Bronze plans can have more volatile margins, early 2026 performance has been "consistent with expectations".[32]
A critical component of Marketplace profitability is the risk adjustment mechanism, which redistributes funds among insurers based on the health status (morbidity) of their enrollees. In Q4 2025, Centene was in a "meaningful payable position" (owing money to the pool), but in Q1 2026, management shifted its forecast to a "slight receivable".[28]
However, there remains substantial uncertainty regarding the final risk adjustment numbers. Management has emphasized that their revised 2026 guidance does not yet reflect the "full suggested risk adjustment offset".[28, 35] The release of the "June Wakely data"—an industry-wide report on risk adjustment trends—will be a key catalyst for the company in the second half of 2026.[28, 37]
The Medicare segment has been a major contributor to Centene’s 2026 revenue growth, with Q1 revenue increasing 18% to $10.3 billion.[7] This performance is driven by the Prescription Drug Plan (PDP) business, where membership surged to 8.78 million members.[7]
The IRA introduced sweeping changes to the Medicare Part D benefit, including a redesign of the risk-sharing programs and a cap on out-of-pocket costs for seniors.[1, 4] These changes have created both challenges and opportunities for Centene. While the program changes initially pressured margins in late 2025, the company has seen strong "premium yield and membership growth" in its stand-alone PDP business in 2026.[4, 7, 27]
Centene has also utilized its PDP receivables to strengthen its balance sheet. In Q1 2026, the company sold a $1.0 billion interest in its 2025 plan year PDP receivables, using the proceeds to repurchase $1.0 billion of senior notes.[6, 7, 29, 39]
In the Medicare Advantage (MA) business, Centene is continuing its multi-year "path to breakeven".[6, 18, 28] Historically, the company has struggled with Star ratings, which impact the quality bonuses paid by the Centers for Medicare & Medicaid Services (CMS).[2, 17] However, management has made Star rating improvement a top priority under its "Value Creation" program.[2, 17]
The 2027 Medicare Advantage rate notice, finalized in April 2026, provided a "sector-wide tailwind" for the industry. CMS approved a 2.48% rate increase for 2027, which was significantly higher than the 0.09% increase proposed in January.[38, 40] This increase will add more than $13 billion in payments to the industry, improving the economics for Centene’s MA business as it moves toward 2027.[38]
The OBBBA is the most significant piece of healthcare legislation in recent years, aiming to reduce the federal deficit by restructuring healthcare financing.[11] Its provisions are wide-ranging and affect every segment of Centene's business.
The OBBBA introduces caps on state Medicaid financing mechanisms that have historically been used to leverage federal funds. Specifically, the bill gradually reduces the cap on provider taxes from 6% to 3.5% by 2032.[9, 11, 12] These taxes are a critical tool for states to fund the "non-federal share" of Medicaid, and their reduction could lead to significant budget shortfalls at the state level.[9, 11]
The bill also restricts "state-directed payments" (SDPs).[9, 12] SDPs are used by states to require managed care plans to pay specific amounts to certain providers. The OBBBA prevents states from establishing directed payment rates that exceed 100% of the Medicare rate in expansion states and 110% in non-expansion states.[9, 12] For Centene, which relies on these payments to support its provider networks, these restrictions could limit its ability to manage provider relationships and maintain network adequacy.[22]
On a more positive note, the OBBBA aims to simplify and digitize the U.S. healthcare payment system.[10] It includes provisions for billing standardization and digital infrastructure, which Centene stands to gain from given its scale and prior investments in IT.[10] By digitizing the billing process, the law could reduce administrative inefficiencies and improve claims accuracy, potentially lowering the SG&A ratio over the long term.[10]
However, the transition to these new systems will require substantial near-term investment. Centene’s "Value Creation" plan already includes significant spending on "modernizing and standardizing processes" to manage medical cost trend, which aligns with these legislative requirements.[35]
As of late April 2026, Centene’s stock (NYSE: CNC) is trading in a state of "recovery," as investors weigh the strong Q1 results against the long-term risks of the OBBBA.[31, 38]
The stock has shown significant momentum in early 2026. Following the April 28 earnings beat, the stock rose 6% in pre-market trading, reaching approximately $44.91.[8]
| Stock Metric (04/20/2026) | Value | 52-Week Range |
|---|---|---|
| Current Price | $38.31 | $25.08 – $64.15 |
| 50-Day Moving Average | $38.28 | N/A |
| 100-Day Moving Average | $40.07 | N/A |
| 200-Day Moving Average | $36.10 | N/A |
| Market Cap | $21.39B | N/A |
[41, 42, 43, 44]
The stock is currently trading above its 200-day moving average of $36.10, which technical analysts interpret as a sign of a structural recovery from the 2025 lows.[42, 44] Despite being down year-to-date, the stock has gained over 25% in the last month, reflecting a "bullish" shift in sentiment among institutional investors.[43]
Estimating the Weighted Average Cost of Capital (WACC) for Centene requires an assessment of its current debt load and equity risk premium. Centene’s total debt was reduced to $16.4 billion in Q1 2026, with a debt-to-capitalization ratio of 43.2%.[6, 7]
Using a 2-stage Free Cash Flow to Equity (FCFE) approach, Simply Wall St estimates the intrinsic value of Centene at $201.45 per share, suggesting that the stock is nearly 80% undervalued at current levels.[31] This model assumes that the company can successfully navigate the OBBBA and restore its Medicaid and Marketplace margins.
More cautious "Centene Narratives" suggest a fair value closer to $32.00, assuming that regulatory scrutiny and changing membership patterns will continue to pressure margins.[31] The mean price target among 17 Wall Street analysts is approximately $43.18, implying about 23% upside from current levels.[37]
Centene’s leadership team, led by CEO Sarah London and CFO Andrew Asher, has undergone a "reshaping" in recent months to better align with the new regulatory environment.[5, 28]
The tone of management in recent earnings calls has been "slightly positive" in prepared remarks but "technical and defensive" during Q&A.[28] Management has consistently used the word "prudent" to describe their 2026 guidance, emphasizing that they are not yet fully accounting for potential upsides in risk adjustment or medical cost trends.[28, 35]
The company’s strategic priorities for 2026 and beyond include:
According to the 2026 Proxy Statement, the company’s incentive compensation plans are increasingly tied to "quality metrics," such as CMS Star ratings and state-based quality scores, rather than just membership growth.[17, 18] This shift is intended to align executive rewards with the long-term goal of "restoring the enterprise's embedded earnings power".[18, 21]
Centene competes with a group of large, diversified insurers that have different levels of exposure to government programs.[24, 34]
UnitedHealth remains the industry "bellwether," with a highly diversified portfolio that includes Optum, its pharmacy and provider services arm.[10, 34] UnitedHealth’s Q1 2026 earnings beat, reporting adjusted EPS of $7.23, served as a "positive read-through" for the entire sector, signaling easing medical cost pressures.[40]
Elevance Health (formerly Anthem) has a strong "Blue-branded" presence and is a frequent head-to-head competitor for large state Medicaid contracts.[34, 45] Elevance has historically maintained higher margins than Centene, but it also faces challenges in its Medicaid business due to redeterminations.[24]
Molina is Centene’s closest peer, as both companies focus heavily on government programs.[10, 24, 45] However, Molina’s stock plunged 33% in early February 2026 after the company forecast 2026 profit at less than half of analyst expectations.[32, 46] This was due to Molina's view that the Medicaid market remains "underfunded by 300-400 basis points".[24] Centene’s ability to raise its guidance while Molina lowered its has created a significant "valuation gap" between the two firms.[32]
| Managed Care Peer Valuation | Price/Earnings (FWD) | Price/Sales (FWD) | Net Margin |
|---|---|---|---|
| Centene | 14.4x | 0.11x | -3.4% (TTM) |
| UnitedHealth | 18.5x (est) | 1.25x (est) | 5.5% (est) |
| Elevance Health | 15.1x | 0.39x | 2.8% |
| Molina Healthcare | 22.1x | 0.25x | 3.2% |
| Humana | 22.8x | 0.21x | 0.9% |
[26, 31, 38, 41, 45]
Centene’s P/S ratio of 0.11x is the lowest among its peers, reflecting the market’s concern over its low margins and its high degree of exposure to the Medicaid segment.[31, 41]
Looking ahead to the late 2020s, Centene’s success will be defined by its ability to manage the "double-edged sword" of the OBBBA.
The total addressable market for U.S. health and medical insurance is projected to reach $2.15 trillion by 2031, with a 5.37% CAGR.[47] While Medicaid enrollment is expected to decline, the Medicare Advantage segment is forecasted to expand at a 9.73% CAGR through 2031.[47] For Centene, this means that growth will likely shift from Medicaid toward Medicare and "micro-insurance" offerings enabled by AI-driven risk stratification.[47]
The primary risks for Centene include:
To mitigate these risks, Centene is focusing on "actuarial strategy alignment" and "reducing avoidable disenrollment".[22] The company is also exploring expansion into "private markets" to offset potential Medicaid revenue losses.[10]
The transition of Centene Corporation from the structural "reset" of 2025 to the operational "recovery" of 2026 is a significant case study in managed care resilience. The company has demonstrated that even in a period of shrinking membership, it can restore profitability through disciplined pricing and rigorous cost management. The Q1 2026 results, characterized by a massive EPS beat and a raise in full-year guidance, have begun to restore investor confidence and have positioned the stock for a "bullish re-rating".[26]
However, the long-term impact of the One Big Beautiful Bill Act (OBBBA) cannot be ignored. The law represents a fundamental shift toward fiscal austerity in the Medicaid program, which will require Centene to become even more efficient in its operations. The enterprise's ability to navigate semi-annual redeterminations and work requirements will be the defining challenge of the 2027-2030 period.
Strategic Recommendations for Centene Management:
By executing on these priorities, Centene can move beyond its 2025 trough and emerge as a leaner, more resilient leader in the government-sponsored healthcare market. The enterprise's massive scale and localized depth remain its greatest assets, and its ability to adapt to the new legislative reality will determine its valuation through 2030.
View Centene Corporation (CNC) stock page
Loading the interactive version of this report…